Trastuzumab Therapy Considerations

Cardiac Monitoring and Toxicity

The National Comprehensive Cancer Network (NCCN) guidelines emphasize that cardiac toxicity is a critical safety concern with trastuzumab, with a 4% risk when used as monotherapy and up to 27% when combined with anthracyclines 1.
The FDA recommends evaluating left ventricular ejection fraction (LVEF) prior to and during treatment, with assessment every 3 months during therapy 2.
Increased cardiac toxicity has been consistently observed in patients treated with trastuzumab, particularly when combined with anthracycline and taxane-based regimens 2.

Trastuzumab consistently demonstrates significant mortality reduction, with an average absolute reduction in 10-year breast cancer mortality by 6.4% (95% CI, 4.9-7.8; P<0.0001) and reduction in all-cause mortality by 6.5% (95% CI, 5.0-8.0; P<0.0001) 2.
The NCCN recommends up to 1 year of HER2-targeted therapy with trastuzumab based on the protocol design of randomized trials establishing trastuzumab benefits 2.
For metastatic/stage IV disease, the NCCN recommends continuing HER2-targeted therapy until progression or unacceptable toxicity 3.

The NCCN guidelines do not identify PPIs as contraindicated medications or drugs requiring special monitoring when used with trastuzumab 4, 5, 2, 3.
The American College of Cardiology and other guideline societies do not recommend discontinuing or delaying trastuzumab therapy due to concomitant PPI use, as no evidence supports this practice 4, 5, 2, 3.

The NCCN guidelines note that biotin interference with HER2 diagnostic assays is a concern, and patients should discontinue biotin supplements at least 72 hours (preferably 7 days for high doses) before HER2 testing to avoid false results in streptavidin-biotin immunoassays 1.
Once HER2-positive status is properly confirmed, the NCCN recommends not withholding trastuzumab due to any supplement use, including biotin, as early treatment provides maximum survival benefit 1.

CLEOPATRA phase III trial: Adding pertuzumab to trastuzumab and docetaxel did not produce a statistically significant rise in either symptomatic or asymptomatic cardiac dysfunction versus trastuzumab + docetaxel alone, indicating that pertuzumab does not add measurable cardiac risk in this regimen (Level I evidence – randomized controlled trial) 6.

National Comprehensive Cancer Network (NCCN) guideline: The NCCN strongly advises against administering pertuzumab together with trastuzumab and anthracycline‑based chemotherapy because the combination is linked to a 27 % incidence of clinically significant cardiac dysfunction, representing a high‑risk scenario (expert consensus/grade B recommendation) 7.